We found that similar to dasatinib, STAT5B-specific shRNA synergized with BMS-345541 in conferring the best chemosensitization effect, again indicating that co-inhibition of STAT5 and NF-κB is a promising strategy for the treatment of carboplatin-resistant ovarian cancers (Figure 6C). The gene discussed is NFKB1; the disease is ovarian cancer.